SCHEMBL31260412

SCHEMBL31260412

O=Cc1ccc(Br)c2[nH]ccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM3 Q86V86 6/20 0.44
PIM1 P11309 4/20 0.44
PIM2 Q9P1W9 2/20 0.38
DRD4 P21917 2/20 0.36
DRD3 P35462 2/20 0.36
CYP2A6 P11509 3/20 0.36
TRIM24 O15164 1/20 0.36
TRIM33 Q9UPN9 1/20 0.36
DRD2 P14416 1/20 0.35
PARP1 P09874 1/20 0.35
AHR P35869 1/20 0.34
CCR8 P51685 2/20 0.33
KMT2A Q03164 2/20 0.32
PRKCI P41743 1/20 0.32
IMPDH2 P12268 1/20 0.32
CCR1 P32246 1/20 0.31
CCR5 P51681 1/20 0.31
MEN1 O00255 1/20 0.30
LMNA P02545 1/20 0.30
THRB P10828 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29935605 0.77 ERN1 (0.37) PIM3PIM1PIM2CYP2A6TRIM24
SCHEMBL673396 0.77 TDP1 (0.39) PIM3PIM1PIM2CYP2A6TRIM24
SCHEMBL15652400 0.77 TRIM24 (0.56) PIM3PIM1PIM2CYP2A6TRIM24
SCHEMBL2124264 0.77 AHR (0.48) PIM3DRD4DRD3DRD2PARP1
SCHEMBL29556631 0.77 AHR (0.48) PIM3DRD4DRD3DRD2PARP1
SCHEMBL4235104 0.73 ALDH1A1 (0.43) TRIM24TRIM33KMT2ALMNATDP1
SCHEMBL29953184 0.72 PIM3 (0.77) PIM3PIM1PIM2CYP2A6TRIM24
SCHEMBL16067373 0.72 PIM3 (0.77) PIM3PIM1PIM2CYP2A6TRIM24
SCHEMBL25407907 0.69 DRD4 (0.39) DRD4DRD3DRD2PARP1AHR
SCHEMBL620047 0.69 TNF (0.39) DRD4DRD3DRD2PARP1AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4716685-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2026-04-01 EP disclosed
US-20260070906-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2026-03-12 US disclosed
WO-2024240726-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2024-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070906-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER TLR1, TLR6, TLR8 PIM3 2194/4885PIM1 1452/4885PIM2 1656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.